MSD recruit Taiho and Astex to assist in developing KRAS therapies

MSD announces worldwide research collaboration and license agreement with Taiho Pharmaceutical and Astex Pharmaceuticals, both subsidiaries of Otsuka, to develop small molecule inhibitors against several drug targets. It was revealed that the partnership intends to investigate drugs including the KRAS oncogene, which are currently being investigated for the treatment of cancer. KRAS is among the

Continue Reading

AZ and Novoheart create a 3D heart model

AstraZeneca and Novoheart are collaborating on developing a functioning miniature human heart model of heart failure, a first of its kind. The ‘heart-in-a-jar’, Novoheart’s proprietary 3D human ventricular cardiac organoid chamber (hvCOC) technology, will be made from human stem cells and will replicate the key characteristics of heart failure. This will include preserved ejection fraction

Continue Reading

£1.2m cash injection to be given to Stevenage Bioscience

Hertfordshire Local Enterprise Partnership announced plans to invest an extra £1.2 million into Stevenage Bioscience Catalyst (SBC), in order to “help grow a world-class cell and gene therapy cluster.” The money will help reinforce the campus as a world class cell and gene therapy cluster, providing much-needed temporary accommodation for growing companies of that nature.

Continue Reading

GSK and Lyell to collaborate on cancer cell therapies

GSK and Lyell Immunopharma have announced a five-year collaboration to develop new technologies with the aim of improving cell therapies for cancer patients. In the announcement the companies explained that the collaboration will apply Lyell’s technologies to further strengthen GSK’s cell therapy pipeline, including GSK3377794, which targets the NY-ESO-1 antigen that is expressed across multiple

Continue Reading

Novartis and Microsoft join together to transform medicine using AI

Novartis and Microsoft have announced a new collaboration with the aim to “transform medicine with artificial intelligence.” Novartis announced the “important step in reimagining medicine” by founding the Novartis AI innovation lab, choosing Microsoft as its strategic AI and data-science partner. The company says that the new lab will look to bolster Novartis AI capabilities

Continue Reading